Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This cross-talk could potentially provide a novel mechanism for inflammation-induced platelet hyperactivity, so the IL-6-GP130-JAK-STAT3 pathway has been identified as a potential target to block this hyperactivity.
|
31145836 |
2019 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Signal transducer and activator of transcription 3 (STAT3) is commonly hyperactive in many cancers and is associated with cancer cell proliferation, invasion, migration, and angiogenesis.
|
30863721 |
2019 |
Hyperactive behavior
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Hyperactivity of signal transducer and activity of transcription 3 (STAT3) plays a crucial role in melanoma invasion and metastasis.
|
29348670 |
2018 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In aggregate, our data link the loss of Abi-1 function to hyperactive SFKs/STAT3/NF-κB signaling and suggest that this signaling axis may represent a regulatory module involved in the molecular pathophysiology of PMF.
|
30213875 |
2018 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In contrast, STAT3 hyperactivity is not usually related to hyperphosphorylation but rather to increased STAT3-mediated transcriptional activity.
|
28914637 |
2017 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In mESCs, acetyl-LIFR undergoes homodimerization, leading to STAT3 hypo- or hyper-activation depending on the presence or absence of gp130.
|
28122243 |
2017 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These chemicals suppressed the phosphorylation of PTK6 substrate proteins, including signal transducer and activator of transcription 3, in human embryonic kidney (HEK) 293 cells expressing hyperactive PTK6.
|
28454278 |
2017 |
Hyperactive behavior
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Autosomal dominant hyper-IgE (AD-HIES) is a primary immunodeficiency caused by mutations in STAT3.
|
28167354 |
2017 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, we compared the IL27 responses with those induced by IFNγ (STAT1-dominated response) or IL6-type cytokines (IL6, hyper-IL6 (hy-IL6) or OSM) (STAT3-dominated response) by microarray analysis and find that in HCC cells, IL27 induces an IFNγ-like, STAT1-dependent transcriptional response, but we do not find an effective STAT3-dependent response.
|
27939431 |
2017 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The objective of this research was to develop polymeric micellar formulations of inhibitors of signal transducer and activator of transcription 3 (STAT3) dimerization, i.e., S3I-1757 and S3I-201, and evaluate the activity of successful formulations in B16-F10 melanoma, a STAT3 hyperactive cancer model, in vitro and in vivo.
|
28290050 |
2017 |
Hyperactive behavior
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Germline loss-of-function mutations are known to cause hyper-IgE immunodeficiency (autosomal dominant hyper IgE syndrome), whereas somatic gain-of-function mutations have been described in large granular cell leukemia, and polymorphisms in STAT3 have been associated with inflammatory bowel disease and other solid organ tumors.
|
26574998 |
2016 |
Hyperactive behavior
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The STAT3 DNA binding domain (DBD, 320-494) mutation in hyper immunoglobulin E syndrome (HIES), called the HIES mutation (R382Q, R382W or V463Δ), which elevates IgE synthesis, inhibits SIE binding activity and sensitizes genes such as TNF-α for expression.
|
26384563 |
2015 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hyperactive STAT3 is thought to be oncogenic in PCa.
|
26198641 |
2015 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, enhanced STAT3/NF-κB-BEX2-VEGF signaling pathway contributes to hyperactive mTOR-induced tumorigenesis.
|
26296882 |
2015 |
Hyperactive behavior
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Compared with normal DCs, tumor-associated DCs (TADCs) are less matured with poor responsiveness to Toll-like receptor (TLR) stimulation, which has been related with STAT3 hyperactivity.
|
25457983 |
2015 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.
|
24550394 |
2014 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Genetic reduction of Stat3 hyperactivity in gp130(F/F):Stat3(-/+) mice prevented lung inflammation and excessive protease activity; however, emphysema still developed.
|
22268122 |
2012 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, the ITCs are known to suppress diverse oncogenic signaling pathways often hyperactive in human cancers (e.g. nuclear factor-κB, hormone receptors, signal transducer and activator of transcription 3) to elicit cancer chemopreventive response.
|
22739026 |
2012 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Previous work has instead suggested that STAT3 activation in solid tumors is more commonly induced by hyperactive growth factor receptors or autocrine cytokine signaling.
|
22319590 |
2012 |
Hyperactive behavior
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Of all the causes identified for the disease hyper-immunoglobulinemia E syndrome (HIES), a homozygous mutation in tyrosine kinase2 (TYK2) and heterozygous mutations in STAT3 are implicated the defects in Jak/STAT signalling pathway in the pathogenesis of HIES.
|
22581330 |
2012 |
Hyperactive behavior
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Western blot analysis showed that these EGFR mutations enhanced cell growth and invasion via constitutive and hyperactive tyrosine phosphorylation and led to the activation of mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3) and Akt pathways.
|
18193092 |
2008 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Prior studies from this group have shown that Stat3 hyperactivity stimulates the TGF-beta inhibitor Smad7.
|
18431518 |
2008 |